Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2

Ling-Yen Chung1, Shye-Jye Tang6, Guang-Huan Sun3, Teh-Ying Chou4, Tien-Shun Yeh2, Sung-Liang Yu5, and Kuang-Hui Sun1

Abstract

Purpose: This study is aimed at investigating the role and novel molecular mechanisms of galectin-1 in lung cancer progression.

Experimental Design: The role of galectin-1 in lung cancer progression was evaluated both in vitro and in vivo by short hairpin RNA (shRNA)-mediated knockdown of galectin-1 in lung adenocarcinoma cell lines. To explore novel molecular mechanisms underlying galectin-1–mediated tumor progression, we analyzed gene expression profiles and signaling pathways using reverse transcription PCR and Western blotting. A tissue microarray containing samples from patients with lung cancer was used to examine the expression of galectin-1 in lung cancer.

Results: We found overexpression of galectin-1 in non–small cell lung cancer (NSCLC) cell lines. Suppression of endogenous galectin-1 in lung adenocarcinoma resulted in reduction of the cell migration, invasion, and anchorage-independent growth in vitro and tumor growth in mice. In particular, COX-2 was downregulated in galectin-1–knockdown cells. The decreased tumor invasion and anchorage-independent growth abilities were rescued after reexpression of COX-2 in galectin-1–knockdown cells. Furthermore, we found that TGF-β1 promoted COX-2 expression through galectin-1 interaction with Ras and subsequent activation of p38 mitogen-activated protein kinase (MAPK), extracellular signal–regulated kinase (ERK), and NF-κB pathway. Galectin-1 knockdown sensitized lung cancer cells to platinum-based chemotherapy (cisplatin). In addition, galectin-1 and COX-2 expression was correlated with the progression of lung adenocarcinoma, and high clinical relevance of both proteins was evidenced (n = 47).

Conclusions: p38 MAPK, ERK, and COX-2 activation are novel mediators for the galectin-1–promoted tumor progression and chemoresistance in lung cancer. Galectin-1 may be an innovative target for combined modality therapy for lung cancer.

Clin Cancer Res; 18(15); 4037–47. ©2012 AACR.
Translational Relevance

Targeted therapeutic approaches have been indicated to improve standard chemotherapy. EGF receptor (EGFR) inhibitors have been commonly used in lung cancer treatment. Unfortunately, clinical data show that only 10% of patients with non–small cell lung cancer (NSCLC) respond to EGFR inhibitors. Our studies provide insight into the influence of galectin-1, which is increasingly recognized as an important factor of regulatory proteins, in lung cancer development. Suppression of galectin-1 elicits antitumor activity both in vitro and in vivo and inhibits cancer-relevant signaling pathways in NSCLCs. Furthermore, galectin-1 is highly expressed in lung cancer tissues from patients with stage III NSCLCs, indicating that galectin-1 may be a predictor for outcome of patients with NSCLCs. In addition, galectin-1 knockdown sensitized lung cancer cells to platinum-based chemotherapy (cisplatin). These results suggest that galectin-1 may be a biomarker for prognosis and an innovative target for combined modality therapy for lung cancer.

Promotes immunosuppression by inducing apoptosis of activated T cells (9). It also contributes to various steps in tumor progression such as transformation, angiogenesis, and metastasis (10). It has been reported that galectin-1 exhibits opposing biologic effects, depending on the physicochemical properties of the protein and the target cell type and status (11). Extracellular galectin-1–induced antiproliferative effects result from the inhibition of the Ras/mitogen-activated protein (MAP)-ERK (MEK)/extracellular signal–regulated kinase (ERK) pathway and transcriptional induction of p27 (12), whereas intracellular galectin-1 exhibits specificity toward H-Ras and triggers the ERK pathway for tumor transformation (13, 14). Moreover, galectin-1 accumulation in the peritumoral stroma of ovary and breast carcinomas regulates both cancer cell proliferation and invasiveness (15–17). Recent studies report that galectin-1 activates carcinoma-associated fibroblasts and increases MCP-1 secretion of oral squamous cell carcinoma, which promotes tumor progression and metastasis (15). The contradictory effects of galectin-1 on regulating cancer progression still remain to be elucidated.

Galectin-1–expressing lung tumors have been shown to have poor prognosis (18). Invasiveness of tumor cells has shown to correlate positively with the expression level of galectin-1 (19). However, the molecular mechanisms of galectin-1 in progression of lung cancer remain unclear. In this study, we investigated the roles of galectin-1 in lung cancer and further identified which molecular pathway contributes to galectin-1–promoted cancer progression and chemoresistance in lung adenocarcinoma and that galectin-1 may be a potential target for drug design in lung cancer therapy.

Materials and Methods

Cell lines

Mouse Lewis lung carcinoma-1 [LLC-1; H-2b; American Type Cell Collection (ATCC no. CRL-1642)] and human lung adenocarcinoma A549 (ATCC no. CCL-185) were obtained from BioResources Collection and Research Center. Human NSCLC cell lines including adenocarcinoma (EKVX, HOP62, NCI-H23, and NCI-H522), large cell carcinoma (HOP92 and NCI-H460), squamous cell carcinoma (NCI-H226), and bronchioloalveolar cell carcinoma (NCI-H322M) cell lines were purchased from the National Cancer Institute (Bethesda, MD). PC-9 lung adenocarcinoma cell line was a kind gift from Dr. A. Maan-Yuh Lin (National Yang-Ming University, Taipei, Taiwan). HEK293T cell line was a kind gift from Dr. Jason C. Huang (National Yang-Ming University).

Mouse model

Male C57BL/6 (H-2b; 6–8 weeks of age) mice were purchased from National Laboratory Animal Center (Taipei, Taiwan). These animals were raised under specific pathogen-free conditions in the Animal Center of National Yang-Ming University in accordance with the regulations of the Animal Care Committee of National Yang-Ming University. To determine the tumor growth in vivo, C57BL/6 mice were subcutaneously inoculated with tumor cells (2 × 10^6)/100 μL cells). Tumor volume was measured with a caliper and calculated as length × width × height (in cm^3) at intervals of 3 days.

Tissue microarrays and immunohistochemistry

Tissue array slides were purchased from Biomax (US Biomax, Inc.). The company provided certified documents that all human tissue samples were collected with informed consent from the donors and their relatives. Our research was reviewed for exempt status by the Institutional Review Board. The detailed clinicopathologic characteristics of 82 patients with lung cancer are listed in Supplementary Table S1. The tissue sections were deparaffinized, and then the slides were heated in 10 mmol/L citrate buffer (pH6.0) at 120°C for 20 minutes for antigen retrieval. Nonspecific binding was blocked with 3% H2O2 for 5 minutes. Then, they were reacted with galectin-1 or COX-2 primary antibodies at 4°C overnight. The subsequent steps were carried out using LSAB+ System-HRP kit (DAKO). In addition, the...
sections were counterstained with hematoxylin. A digital pathology system for stained cells scoring was conducted by Aperio ImageScope (Aperio Technologies, Inc.). The score of tumor cells staining was determined by the sum of percentage and intensity of stained cells to evaluate the protein expression level (20).

Galectin-1 knockdown with short hairpin RNA

HEK293T cells (2.4 × 10^5/mL) were used to produce lentiviral-expressing short hairpin RNA (shRNA) viruses against galectin-1 (shGa-1) or luciferase as a negative control (shLuc) by cotransfection of pLKO.1-shGal-1, pCMV-ΔR8.91, and pMD.G vectors (National RNAi core Facility, Academia Sinica, Taipei, Taiwan). LLC-1 and A549 cells (10^5 cells/mL) were infected with shGal-1 or shLuc in the presence of 8 μg/mL protamine sulfate according to the procedures provided from National RNAi core Facility, Academia Sinica. The specific target sequences by shGal-1 are shown in Supplementary Table S2.

Reverse transcription PCR and quantitative reverse transcription PCR

Total cellular RNA was extracted using TRizol reagent (Invitrogen), and 5 μg of extracted RNA samples was reverse transcribed into cDNA according to the manufacturer’s protocol for reverse transcription PCR (RT-PCR; Promega). RT-quantitative PCR (RT-qPCR) was carried out by the SYBR Green Mix containing Thermo-Start DNA polymerase (Bio-Rad), according to the manufacturer’s instructions with regard to an ABI7700 System (Applied Biosystems). The specific primers of RT-qPCR are shown in Supplementary Tables S3 and S4.

Immunoprecipitation and Western blotting

The supernatant or whole-cell lysates of A549 cells were harvested and immunoprecipitated by indicated primary antibodies (1 μg) or nonspecific IgG as a negative control which was conjugated to protein G magnetic beads (20 μL; Millipore) at 4°C overnight. The complexes were resolved by 13% SDS-PAGE and then transferred to nitrocellulose. The membrane was blotted with indicated primary antibodies and then with horseradish peroxidase (HRP)-conjugated secondary antibodies. The antibodies used in this study are shown in Supplementary Table S5.

Cytoplasm and nucleus of cells were separated by using the CNMCS Compartimental Protein Extraction Kit (BioChain). Whole-cell lysates (60 μg) or nuclear or cytosolic fractionation of cell lysates (20 μg) were separated by 13% SDS-PAGE and then blotted with indicated antibodies.

Cell proliferation in vitro

shLuc- or shGa-1–infected LLC-1 or A549 cells (2.5 × 10^3 cells/mL) were seeded onto 96-well plates and cultured in complete medium up to day 5. The cell proliferation was measured at indicated time by CellTiter 96 aqueous non-radioactive cell proliferation assay (MTS assay) according to the manufacturer’s instructions (Promega).

Invasion and migration assay

The invasive and migratory abilities of tumor cells were evaluated by Transwell assay (Costar, 8-μm pore; Corning) as previously described (21). In invasion assay, Transwell inserts were additionally coated with Matrigel (BD Biosciences).

Anchorage-independent growth assay

LLC-1 (1,000 cells per 6-well) or A549 (2,000 cells per 6-well) cells suspended in 0.33% Bacto agar (Sigma-Aldrich) were layered over 0.5% Bacto agar. After incubation for 20 days, these cells were fixed and stained with Giemsa stain for calculating the number of colonies.

Reporter assay

A549 cells were cotransfected with pGL2-COX-2-luc or pGL3-NFκB-luc and pRL-SV40. After 24-hour transfection, the medium was replaced with complete medium containing 5 ng/mL of TGF-β1. Forty-eight hours later, the luciferase activity was measured using the Dual-Luciferase Reporter Assay System Kit according to the manufacturer’s instructions (Promega).

Statistics

Data were expressed as mean ± SD, and statistical significance was assessed by the ANOVA test. For human tissue microarray studies, a nonparametric Mann–Whitney U test was used to test gene expression relevance between different stages. For dual staining of human tissue microarrays, the Spearman correlation method was used to evaluate the association of scores. A significant difference was declared if the P value was <0.05.

Results

Galectin-1 was overexpressed in NSCLC cell lines

Initially, to examine the expression of different types of galectin in lung cancer cells, mRNA levels of galectins in LLC-1 cells were detected and normalized against the expression of those in normal lung isolated from mice. Elevated mRNA levels of most of galectin members were found in LLC-1 cells and the highest expression of galectin-1 among them was noted (Fig. 1A). Furthermore, we confirmed expression of galectin-1 in 9 human lung cancer cell lines, including adenocarcinoma, large cell carcinoma, squamous cell carcinoma, and bronchioloalveolar cell carcinoma. Most of the human lung cancer cell lines highly expressed galectin-1 (Fig. 1B). To investigate whether galectin-1 expression was correlated with the progression of lung adenocarcinoma, immunohistochemical staining was conducted on a tissue microarray containing samples from 47 patients with different stages of lung adenocarcinomas (Fig. 1C; Supplementary Fig. S1A). Higher levels of galectin-1 in stage III lung adenocarcinoma were evidenced compared with stage I or II. In contrast, there was no significant correlation between galectin-1 expressions in different stages of squamous cell carcinomas (Supplementary Fig. S1B).
Next, to identify the sublocalization of galectin-1 protein in A549 lung cancer, cells were fractionated into cytoplasm and nucleus (Fig. 1D, top). In addition, it is well known that galectin-1 protein can be secreted through nonclassical secretory pathway (22). The supernatant of cell culture was immunoprecipitated and Western blotted using anti-galectin-1 antibody to detect levels of secreted galectin-1 (Fig. 1D, bottom). Galectin-1 protein was expressed in the nucleus and cytoplasm of cells. Nevertheless, it was revealed that quite low level of galectin-1 protein was secreted from A549 cells. The secretion level of galectin-1 from A549 cells was only 1.2 pg per 10^6 cells (data not shown).

**Suppression of galectin-1 in lung adenocarcinoma cells resulted in reduction of the cell migration, invasion, and anchorage-independent growth in vitro and tumor growth in vivo**

To examine the role of galectin-1 in lung cancer progression, lentivirus-mediated delivery of galectin-1 shRNA (shGal-1) was used to reduce galectin-1 expression in mouse LLC-1 and human A549 cell lines. Compared with cells infected with control virus–expressing luciferase (shLuc), cells infected with shGal-1 virus expressed low levels of galectin-1 (Fig. 2A; Supplementary Fig. S1C). Galectin-1 knockdown significantly inhibited both migratory and invasive abilities of infected cells (Fig. 2B). Furthermore, galectin-1 silencing significantly restrained the anchorage-independent growth of lung cancer cells (Fig. 2C) whereas no effect on the monolayer growth in vitro was observed (Supplementary Fig. S1D). To further evaluate whether galectin-1 could promote tumor growth in vivo, shGal-1- or shLuc-infected LLC-1 cells were injected subcutaneously into mice. As shown in Fig. 2D, tumor growth was reduced in mice injected with shGal-1–infected cells. Therefore, galectin-1 might promote migration, invasion, and anchorage-independent growth of lung cancer cells and tumor growth in mice.

**Intracellular galectin-1 promoted expression of COX-2 and PGE2**

We further explored which mechanisms contributing to tumor progression were regulated by galectin-1. We analyzed tumorigenic-associated gene profiles by RT-PCR and RT-qPCR in parental, shLuc-, and shGal-1–infected cells. The mRNA levels of COX-2 were significantly
downregulated in both galectin-1 silencing of A549 and LLC-1 cells (Fig. 3A; Supplementary Fig. S2A). VEGF was repressed in LLC-1/shGal-1 but not significantly affected in A549/shGal-1 cells (Fig. 3A; Supplementary Fig. S2A). Furthermore, the COX-2 protein expression and PGE2 release were examined in A549/shGal-1 and LLC-1/shGal-1 cells (Fig. 3B; Supplementary Fig. S2B). We confirmed the reduction of COX-2 protein and PGE2 secretion as a result of galectin-1 knockdown in lung adenocarcinoma cells. In addition, to explore whether exogenous galectin-1 contributed to induction of COX-2 expression, A549 cells were treated with human recombinant galectin-1 (100 ng/mL) and RT-PCR and Western blotting were carried out (Fig. 3C). There was no significant increase in COX-2 expression upon treatment with exogenous galectin-1. Therefore, we suggest that endogenous but not exogenous galectin-1 regulates expression of COX-2.

**COX-2 activation contributed to galectin-1–promoted cancer cell migration, invasion, and anchorage-independent growth**

To confirm the effects of galectin-1 on COX-2 activation, shGal-1–infected A549 cells were transiently transfected with galectin-1 cDNA or pcDNA3 empty vector (shGal-1/Gal-1 or shGal-1/pc). As expected, COX-2 expression (Supplementary Fig. S2C) and PGE2 production (Fig. 4B) were recovered in shGal-1/Gal-1 cells. Moreover, reexpression of galectin-1 led to restore the migratory (Fig. 4C, left) and invasive abilities (Fig. 4C, right) as well as anchorage-independent growth (Fig. 4D) of A549/shGal-1 cells. We also used H522 cells that expressed lower levels of galectin-1 (Fig. 1B) to confirm the effects of galectin-1/COX-2 axis on tumor progression. H522 cells were transfected with galectin-1 cDNA or pcDNA3 empty vector (Supplementary Fig. S3A). We found that mRNA and protein levels of COX-2 were concordantly increased after overexpression of galectin-1 in H522 cells (Supplementary Fig. S3A). In addition, tumor migration, invasion, and anchorage-independent cell growth were significantly upregulated in galectin-1–overexpressed H522 cells (Supplementary Fig. S3B and S3C).

Next, to prove whether COX-2 activation contributed to galectin-1-mediated cancer cell migration, invasion, and in vivo tumor growth, shGal-1–infected A549 cells transiently expressed COX-2 cDNA or empty vector (shGal-1/COX-2 or shGal-1/pc). After overexpression of COX-2, expression of COX-2 (Fig. 4A) and PGE2 (Fig. 4B) was both recovered in shGal-1/COX-2 cells, whereas mRNA and protein levels of galectin-1 did not change, suggesting that galectin-1 was upstream of COX-2. Percentage of migratory and invasive cells was rescued in COX-2–overexpressing A549/shGal-1 cells (Fig. 4C). The
anchorage-independent growth was also restored in shGal-1/COX-2 cells as shown in Fig. 4D. These results suggest that COX-2 activation contributes to the galectin-1–mediated tumor progression.

**TGF-β1 induced COX-2 transcription via galectin-1 and MAPK/NF-κB activation**

The expression of COX-2 is induced by several extracellular stimuli, one of which is growth factors, including TNF,
TGF, and EGF (23). Recent reports indicate that TGF-β1 regulates COX-2 promoter activity through several signaling routes including activation of p38 MAPK and ERK pathway by directly binding to COX-2 promoter. Furthermore, it has been indicated that TGF-β1 may trigger a Smad-dependent pathway to control galectin-1 expression in metastatic mammary adenocarcinoma (26). Therefore, we investigated whether galectin-1 knockdown affected the COX-2 expression induced by TGF-β1 in lung cancer cells. COX-2 promoter activity was analyzed using luciferase reporter assay upon treatment of TGF-β1 in shLacZ- or shGal-1–infected A549 cells. TGF-β1 increased the COX-2 promoter activity (Supplementary Fig. S2D) and protein levels of galectin-1 and COX-2 (Fig. 5A).

We next defined the TGF-β1 signaling pathways in galectin-1–induced COX-2 expression. We prepared shGal-1–knockdown A549 cells followed by treatment with or without recombinant TGF-β1 protein for 60 minutes. The downstream mediators involved in TGF-β1 signaling, including p38 MAPK, NF-κB, ERK1/2, c-jun-NH2-kinase (JNK), and Akt, were analyzed by Western blotting. As shown in Fig. 5A, p38 MAPK and ERK1/2 phosphorylation was induced by TGF-β1, but the increased levels induced by TGF-β1 were much lower in shGal-1–infected cells than those in shLuc-infected cells. The common downstream gene of p38 MAPK and ERK signaling pathways, NF-κB/p65, was also reduced upon suppression of galectin-1 expression. Nevertheless, Akt and JNK phosphorylation was not affected by TGF-β1 (Fig. 5A).

To confirm the role of NF-κB in galectin-1–mediated expression of COX-2, shLacZ- or shGal-1–infected cells were transfected with pGL3/NF-κB-luc reporter plasmid and treated with TGF-β1. The luciferase activity of NF-κB reporter was markedly reduced by suppression of galectin-1 while rescued by reexpression of galectin-1 (Fig. 5B). Moreover, the promoter activity of COX-2 suppressed by galectin-1

**Figure 5.** TGF-β1 drove galectin-1–regulated COX-2 transcription through p38 MAPK and ERK pathway in lung adenocarcinoma. A, shLuc- or shGal-1–infected cells were treated with or without TGF-β1. One hour later, Western blotting was carried out. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B, shLacZ- or shGal-1–infected A549 cells were cotransfected with pcDNA3 (pc) or galectin-1 (Gal-1), pNF-κB-luc, and pRL-SV40. Twenty-four hours later, cells were treated with TGF-β1 for 48 hours. Luciferase reporter assay was conducted to investigate NF-κB promoter activity regulated by galectin-1. C, shLacZ- or shGal-1–infected A549 cells were cotransfected with pDNA3 (pc) or NF-κB-p65 (p65), pXCl918/COX-2-luc, and pRL-SV40. Twenty-four hours later, cells were treated with or without TGF-β1 for 48 hours. Luciferase reporter assay was conducted to examine COX-2 promoter activity regulated by NF-κB. RLU, relative luciferase units. D, shLuc- or shGal-1–infected A549 cells were subjected to immunoprecipitation (IP) using anti-Ras antibody (right) or anti-Gal-1 antibody (left) and then immunoblotted using anti-Gal-1 antibody or anti-Ras antibody. IgG, negative control. WCL, whole-cell lysate control. Results are representative of 3 independent experiments. (*) P < 0.05; (**) P < 0.01. WB, Western blotting.
knockdown was significantly increased when NF-κB/p65 was overexpressed in shGal-1–infected A549 cells (Fig. 5C). These results suggest that TGF-β1 induces COX-2 expression through galectin-1 and MAPK/NF-κB activation.

**Galectin-1 interacted with H-Ras in lung cancer cells**

It has been reported that intracellular galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation (13). TGF-β1 promotes H-Ras–activated tumor migration and invasion in breast cancer cells (27). Therefore, we investigated whether galectin-1 interacted with Ras in lung cancer cells. The association of galectin-1 and Ras was conducted by co-immunoprecipitation followed by Western blotting. As shown in Fig. 5D, galectin-1 directly interacted with Ras and galectin-1 knockdown reduced the association of galectin-1 and Ras in lung cancer cells.

**Galectin-1 knockdown sensitized lung cancer cells to cisplatin treatment**

COX-2 induction may reduce the response of malignant cells to cytotoxic therapy (28). To investigate the effects of galectin-1 knockdown on chemosensitivity of lung cancer cells, we treated A549/shLuc and A549/shGal-1 cells with cisplatin (IC₅₀ = 20 μmol/L) for up to 48 hours (Fig. 6A and B). A549/shLuc cells increased expression of COX-2 protein time dependently after cisplatin treatment. Galectin-1 knockdown in A549 (A549/shGal-1) attenuated cisplatin-induced COX-2 expression (Fig. 6A, top). In addition, galectin-1 knockdown blocked the cisplatin-induced PGE2 production (Fig. 6A, bottom). Furthermore, shGal-1–infected A549 cells were more sensitive to cisplatin treatment than shLuc-infected cells (Fig. 6B). After cisplatin treatment for 72 hours, the percentage inhibition of cell growth was 92% in shGal-1–infected cells whereas only 55% inhibition in shLuc-infected cells (Fig. 6B). These suggest that COX-2 inhibition via galectin-1 knockdown sensitizes lung cancer cells to cisplatin treatment.

**Galectin-1 promoted lung cancer progression and chemoresistance by upregulating p38, ERK, and COX-2 in EGFR-mutated adenocarcinoma cells**

Because A549 cells harbor KRAS mutation, to explore whether galectin-1–regulated tumor progression is KRAS-specific or universal, the PC-9 cell line, which is known to carry an EGFR exon 19 deletion and KRAS wild-type, was used. Upon knockdown of galectin-1, mRNA and protein levels of both galectin-1 and COX-2 were reduced in PC-9 cells (Supplementary Fig. S4A). Galectin-1 knockdown in PC-9 cells resulted in suppression of tumor migration, invasion, and anchorage-independent cell growth (Supplementary Fig. S4B). The expression of p-p38 MAPK, p-ERK, and NF-κB/p65 was downregulated in shGal-1–infected PC-9 cells (Supplementary Fig. S4C). Furthermore, shGal-1–infected lung cancer cells were more sensitive to cisplatin treatment than shLuc-infected cells (Supplementary Fig. S4D). We suggest that either in KRAS-mutated A549 cells or in EGFR-mutated PC-9 cells, galectin-1 appears to...
regulate p38 MAPK, ERK, and COX-2 expression to promote tumor progression.

Clinical relevance of galectin-1 and COX-2 expression in tissues of lung cancer

COX-2 is highly expressed in 70% of lung adenocarcinomas and can be detected throughout the progression of a premalignant lesion to the metastatic phenotype (29). To examine the clinical relevance of galectin-1 and COX-2 expression, immunohistochemical staining was conducted on tissue microarrays containing samples from 82 patients with lung cancer, including small cell lung cancer and NSCLC. A positive correlation between galectin-1 and COX-2 expression in lung cancer was revealed (Supplementary Fig. S5A). In addition, galectin-1 expression was correlated with COX-2 expression (Fig. 6C) in 47 patients with lung adenocarcinomas. Higher levels of COX-2 in stage III lung adenocarcinoma were addressed than in stage I (Fig. 6D; Supplementary Fig. S5B). However, in squamous cell carcinomas ($n = 17$), although clinical relevance between galectin-1 and COX-2 expression was revealed (Supplementary Fig. S5C), neither galectin-1 nor COX-2 expression was correlated with the progression of squamous cell carcinoma (Supplementary Figs. S1A and S5D). Taken together, expression levels of both galectin-1 and COX-2 were correlated with the progression of lung adenocarcinoma, and furthermore, a significant positive correlation between galectin-1 and COX-2 expression in lung cancer was revealed.

Discussion

In this study, we showed that endogenous galectin-1 may promote lung cancer progression and chemoresistance by increasing p38 MAPK, ERK, and COX-2 expression. Several reports indicate that galectin-1 exhibits opposing effects in that endogenous galectin-1 has growth-promoting whereas exogenous galectin-1 has growth-inhibiting effects (30, 31). Galectin-1 has been found to induce activated T-cell apoptosis (9, 32–34). However, it remains highly controversial as these cells treated with high concentration of recombinant galectin-1 (35, 36) or concentrated supernatant of tumor cell culture (37) in previous studies. The conditioned supernatant obtained from tumor cell culture contains detectable but quite low level of galectin-1 that is not sufficient for induction of apoptosis. More importantly, induction of T-cell apoptosis requires cell–cell physical contact between $T$ cells and tumor cells (9). In this study, we found that lung cancer cells secreted quite low amount of galectin-1 protein and intracellular galectin-1 promoted COX-2 expression. Intriguingly, A549 cells could express $\alpha$-2,3-sialyltransferase 1 (data not shown) that blocks $O$-linked glycan elongation to render resistance of exogenous galectin-1 (38). Treatment of recombinant galectin-1 did not induce cell death of A549 cells. We hypothesize that tumor cells may disrupt galectin-1–induced itself cell death and promote tumor progression resulting from loss of susceptibility to exogenous galectin-1 via altering cell surface glycosylation and overexpression of endogenous galec-
ERK signaling also governs drug resistance in human cancer (46). Therefore, inhibition of the common upstream regulator of p38 MAPK, ERK, and COX-2 signaling, galectin-1, will be more effective for cancer therapy. In conclusion, galectin-1 not only is a critical scaffolding protein and a major regulator of H-Ras nanoclusters for tumor transformation (13) but also may contribute to tumor progression and drug resistance through p38, ERK, and COX-2 pathways. We suggest that a nontoxic anti-galectin-1 drug (galectin-1 knockdown) in combination with a toxic chemotherapeutic agent (cisplatin) may serve as a novel therapeutic modality for lung cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were declared.

Authors’ Contributions
Conception and design: L.-Y. Chung, S.-J. Tang, G.-H. Sun, T.-S. Yeh, K.-H. Sun
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T.-Y. Chou, S.-K. Yu, K.-H. Sun

References

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.-Y. Chung, S.-J. Tang, T.-S. Yeh, K.-H. Sun

Writing, review, and/or revision of the manuscript: L.-Y. Chung, G.-H. Sun, K.-H. Sun

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.-Y. Chung, S.-J. Tang, T.-S. Yeh, S.-L. Yu, K.-H. Sun

Study supervision: S.-J. Tang, G.-H. Sun, K.-H. Sun

Acknowledgments
The authors thank Drs. Jason C. Huang for kindly providing H293T cell line, A. Maan-Yuh Li for kindly providing PC-9 cell line, Wolfgang Dubiel for the pcDNA3-COX-2-Flag plasmid, I. P. Ting for the pFLAG-p65 plasmid, and Ju-Ming Wang for the pGL2-COX-2-luc reporter.

Grant Support
This work was supported by National Science Council (NSC98–2320-B-010-001-MY3, NSC100–2311-B-010-017), Taipei City Hospital, and the Ministry of Education (Aim for the Top University Plan), Taiwan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Published OnlineFirst June 13, 2012; DOI: 10.1158/1078-0432.CCR-11-3348

Downloaded from clincancerres.aacrjournals.org on April 13, 2017. © 2012 American Association for Cancer Research.


Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-3348

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/06/13/1078-0432.CCR-11-3348.DC1

Cited articles
This article cites 46 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/15/4037.full.html#ref-list-1

Citing articles
This article has been cited by 12 HighWire-hosted articles. Access the articles at:
/content/18/15/4037.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.